Model‐Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic Modeling

Johanna Eriksson, Marylore Chenel, Jean‐Yves Gillon(Drugs for Neglected Diseases Initiative), Erik Sjögren, Vijay Satam(Drugs for Neglected Diseases Initiative India), Vishal Goyal(Chandigarh University), Henri Caplain(Drugs for Neglected Diseases Initiative), Stephen Robinson(Drugs for Neglected Diseases Initiative), Isabela Ribeiro(Drugs for Neglected Diseases Initiative)
CPT Pharmacometrics & Systems Pharmacology
February 25, 2025
10.1002/psp4.13309
Cited by 0

Related Papers

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
|PLoS neglected tropical diseases|2017|78
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis
|BMC Public Health|2017|72
AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial
|Clinical Infectious Diseases|2022|53
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
|˜The œLancet. Gastroenterology & hepatology|2021|42